A Phase 2 Study of First-line Sotorasib for Patients With Advanced KRAS G12C-mutant Non-small Cell Lung Cancer

Inclusion Criteria: * Written informed consent * Biopsy-proven metastatic or recurrent non-small cell lung cancer * KRAS G12C mutation on prior tumor biopsy or cell-free DNA (cfDNA) testing * No prior therapy in the advanced setting * Measurable disease per RECIST 1.1 * Karnofsky performance status (KPS) ≥ 70% * Age ≥ 18 * Adequate organ function * Hemoglobin ≥ 9\^9 g/dL * Platelets ≥ 75 x 10\^9/L * Absolute neutrophil count (ANC) \> 1.5 x 10\^9/L * AST \< 3 x ULN (if liver metastases are present, \< 5 x ULN) * ALT \< 3 x ULN (if liver metastases are present, \< 5 x ULN) * Alkali…